ArticleBMC infectious diseases2026
Admission fibrinogen-to-albumin ratio and mortality in older adults hospitalized with pneumonia: a retrospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPneumonia remains a major cause of hospitalization and death among older adults worldwide. Simple bedside biomarkers that capture the host response to infection may help support early risk stratification in routine care. The fibrinogen-to-albumin ratio (FAR) integrates information on inflammation, coagulation, and nutritional status. We explored whether the admission FAR is associated with 30- and 365-day all-cause mortality in older adults hospitalized with pneumonia.
methodsWe conducted a single-center retrospective cohort study of patients aged ≥ 65 years who presented to a fever clinic with acute fever and were subsequently admitted to general medical wards with radiologically confirmed pneumonia in 2021. FAR was calculated from fibrinogen and albumin measured within 24 h of admission. Associations between FAR and 30- and 365-day all-cause mortality were analyzed using multivariable Cox regression and restricted cubic splines.
resultsOf the 339 included older adults with pneumonia, 47 (13.9%) died within 30 days and 78 (23.0%) died within 365 days after admission. In fully adjusted Cox models, a higher admission FAR was associated with increased mortality, with a hazard ratio (HR) per 0.10-unit increase of 1.62 (95% CI, 1.07–2.46) for 30-day all-cause mortality and 1.39 (95% CI, 1.00–1.94) for 365-day all-cause mortality. Restricted cubic spline analyses supported a generally increasing risk of death with a higher FAR at both time points, without strong evidence of marked nonlinearity.
conclusionsAmong older adults hospitalized with pneumonia, a higher FAR at admission was associated with increased 30-day and 365-day all-cause mortality, with a stronger association for short-term mortality. FAR may represent a simple, routinely available biomarker of adverse prognosis in this population, but prospective studies are needed to confirm its clinical utility.
trial registrationNot applicable. This retrospective study was not prospectively registered.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.